logo-loader

Edison Investment Research initiates coverage of Context Therapeutics with valuation of $8.45 per share

Published: 09:06 24 Feb 2022 EST

Context Therapeutics -
Context Therapeutics, headquartered in Philadelphia, is a Nasdaq-listed biopharma company developing novel therapeutics focused on women’s oncology indications

Edison Investment Research has initiated coverage of Context Therapeutics (NASDAQ:CNTX) Inc with a valuation of $134.9 million or $8.45 per share.

The shares are currently trading at $1.81. 

Headquartered in Philadelphia, Context is a Nasdaq-listed biopharma company developing novel therapeutics focused on women’s oncology indications.

READ: Context Therapeutics adds two new executives to strengthen its research and development team

Lead program onapristone extended-release (ONA-XR) is a potential first-in-class progesterone receptor (PR) antagonist being evaluated in several mid-stage clinical programs in advanced breast, endometrial and ovarian cancer, all areas with significant unmet need. 

In April 2021, the company added another preclinical novel compound to the pipeline, in-licensing a bi-specific monoclonal antibody, CLDN6Xcd3.

“With multiple data readouts expected in 2022, we foresee several inflection points in the coming months,” Edison analysts said.

Contact Ritika at ritika@proactiveinvestors.com

Arrow Exploration CEO on Icaco success, record production and next drilling...

Arrow Exploration Corp (TSX-V:AXL, AIM:AXL, OTC:CSTPF) CEO Marshall Abbott talked with Proactive's Stephen Gunnion about the company's latest drilling success at Icaco in Colombia, where the IC-HZ9 well has exceeded production expectations and helped lift corporate output above 7,000 barrels of...

5 hours, 43 minutes ago